Seaport Therapeutics, Inc. SPTX
At closeNov 6, 2026, 4:42 PM EST
After hours · Nov 6, 4:42 PM ET
- YTD
- +8.37%
- 1 year
- +8.37%
- Market cap
- 1.15B
- EPS (ttm)
- -4.35
- Shares out
- 53.53M
- Forward P/E
- -9.00
- YTD return
- +8.37%
- 1-year return
- +8.37%
- Volume
- 227.03K
- Avg volume
- 225.78K
- Open
- 20.85
- Previous close
- 20.39
- Day's range
- 19.77 – 21.75
- 52-week range
- 15.25 – 27.84
- Analysts
- Strong Buy
- Price target
- 37.00 (+72.1%)
- Earnings date
- Feb 1, 2027
5D +1.61 (+8.09%)
Key statistics
- Enterprise value
- 805.74M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 2.90
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- 0
- Total cash
- 290.43M
- Total debt
- 4.69M
- Return on equity
- 0.00%
- Short % of float
- 7.30%
- 50-day average
- 20.77
- 200-day average
- 20.14
Analyst view
Consensus: strong buy
- Target (low)
- 28.00
- Target (mean)
- 37.00
- Target (high)
- 50.00
- Strong buy1
- Buy7
- Hold1
- Sell0
- Strong sell0
Next earnings
Feb 1, 2027
Expected Feb 1, 2027. Consensus EPS estimate -0.55662.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Feb 1, 2027 | Dec 30, 2026 | -0.59 | — | — | — |
| Nov 2, 2026 | Sep 30, 2026 | -0.56848 | -0.49 | +0.08 | +13.81% |
| Aug 3, 2026 | Jun 30, 2026 | -0.62039 | -1.78 | -1.16 | -186.92% |
| Apr 10, 2026 | Mar 31, 2026 | -5.34 | -5.50 | -0.16 | -2.98% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Nov 5, 2026 | JP Morgan | main | Overweight | Overweight |
| Oct 14, 2026 | Canaccord Genuity | init | — | Buy |
| Oct 8, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Sep 25, 2026 | Raymond James | init | — | Strong Buy |
| Sep 10, 2026 | HC Wainwright & Co. | reit | Buy | Buy |
| Aug 26, 2026 | Jones Trading | init | — | Buy |
About Seaport Therapeutics, Inc.
Seaport Therapeutics, Inc., a clinical-stage therapeutics company, focuses on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. It is leveraging its proprietary Glyph platform to advance a pipeline of therapies to address the unmet needs in depression and anxiety. The company's lead product candidate, GlyphAllo (SPT-300 or Glyph Allopregnanolone), is a novel, Glyphed oral prodrug of allopregnanolone, an endogenous molecule that has been clinically validated in third-party trials for the treatment of postpartum depression. Its second product candidate, GlyphAgo (SPT-320 or Glyph Agomelatine), is a novel, Glyphed oral prodrug of agomelatine, a clinically validated anxiolytic and antidepressant that is approved for the treatment of generalized anxiety disorder in Australia and major depressive disorder in Australia and the European Union. The company was founded in 2024 and is based in Boston, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- seaporttx.com
News
JP Morgan Maintains Overweight on Seaport Therapeutics, Raises Price Target to $41 
How Much Upside is Left in Seaport Therapeutics, Inc (SPTX)? Wall Street Analysts Think 77.91% 
Seaport Therapeutics Q3 EPS $(0.49) Beats $(0.58) Estimate 
Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress 
This Entegris Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday 
Canaccord Genuity Initiates Coverage On Seaport Therapeutics with Buy Rating, Announces Price Target of $28 
Seaport Therapeutics To Present Phase 1 Clinical Data For GlyphAgo At The European College Of Neuropsychopharmacology Congress, October 10-13 
HC Wainwright & Co. Reiterates Buy on Seaport Therapeutics, Maintains $50 Price Target 
This Tower Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday - Raymond James Initiates Coverage On Seaport Therapeutics with Strong Buy Rating, Announces Price Target of $46
Your note
Sign in to keep a note on SPTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| ARCH VENTURE PARTNERS XII, LLC | Beneficial Owner of more than 10% of a Class of Security | Purchase | May 3, 2026 | 0 |
| CHEN MICHAEL CUNYUAN PH.D. | Officer | Conversion of Exercise of derivative security | May 3, 2026 | 3,351 |
| GLADSTEIN LANA J.D. | General Counsel | Conversion of Exercise of derivative security | May 3, 2026 | 33,515 |
| HEALY JAMES I | Director | Conversion of Exercise of derivative security | May 3, 2026 | 0 |
| HOMBACH ROBERT J. CPA | Director | Purchase | Jun 21, 2026 | 0 |
| LOEBEL ANTONY M.D. | Officer | Conversion of Exercise of derivative security | May 3, 2026 | 20,109 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Arch Venture Management, Llc | 11.76% | 6,294,951 | 135.34M | Jun 29, 2026 |
| General Atlantic, L.P. | 11.40% | 6,101,582 | 131.18M | Jun 29, 2026 |
| Sofinnova Investments, Inc. | 6.66% | 3,564,871 | 76.64M | Jun 29, 2026 |
| Goldman Sachs Group Inc | 4.07% | 2,178,642 | 46.84M | Jun 29, 2026 |
| Trv Gp VI, LLC | 3.85% | 2,061,222 | 44.32M | Jun 29, 2026 |
| Canada Pension Plan Investment Board | 3.69% | 1,975,791 | 42.48M | Jun 29, 2026 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| JPMorgan Trust II-JPMorgan Small Cap Growth Fund | 1.57% | 840,931 | 18.08M | Jun 29, 2026 |
| Fidelity Mt. Vernon Street Trust-Fidelity Growth Company Fund | 0.92% | 494,890 | 10.64M | Sep 29, 2026 |
| Prudential Sector Funds, Inc.-PGIM Jennison Health Sciences Fund | 0.82% | 438,754 | 9.43M | Aug 30, 2026 |
| VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund | 0.80% | 426,371 | 9.17M | Jun 29, 2026 |
| iShares Trust-iShares Russell 2000 ETF | 0.66% | 355,159 | 7.64M | Sep 29, 2026 |
| T. Rowe Price Health Sciences Fund, Inc. | 0.56% | 299,319 | 6.44M | Jun 29, 2026 |